Showing posts with label Nanotechnology. Show all posts
Showing posts with label Nanotechnology. Show all posts

ReportsandReports - Innovations in Oral Solid Drug Delivery: Advances in nanotechnology, controlled formulations & peptide delivery



This report concentrates on innovations in oral solid dose delivery systems (OSDDS) with an emphasis on the links between start up companies and academic collaborations. It deals with the impact of the difficult economic climate with the restriction on funding and opportunities for partnering projects.
Developments are assessed in relation to understanding the dynamics of the market. For instance the report discusses the loss of patent protection for blockbuster drugs peaking between 2007-2012, loss of patent protection for the first-generation of OSDDS in the last few years, the dearth of NCEs coming through the pipeline and puts new developments in the context of a market that is seeing a decline in its value in some therapeutic areas. It identifies the drivers for new OSDDS and the issues surrounding them.

A key theme is the transition of peptides and proteins from intravenous to oral delivery. The report looks at the competitive landscape, making reference to sales and market dynamics. A recurring theme is the reformulation of old generic drugs to get over inadequacies in the original drug for instance: low solubility, bioavailability, short duration of action, high side effect potential, poor stability, poor absorption following oral administration, bitter or unpleasant taste, narrow GI absorption window and inter- and intra-patient variability in absorption.

With a growing geriatric population and with people living longer much of the emphasis is on development of OSDDS drugs to more effectively treat diseases of an aging population such as Alzheimer’s disease, Parkinson’s disease, type 2 diabetes and obesity, osteoporosis, cancer and rheumatoid arthritis, etc. Often these treatments have side effects, problems with dosing and short duration of action or have to be administered by injection which reduces their acceptability.

Key features of this report
  • Analysis of innovative platform technologies, companies and product development pipelines involved in transitioning injectable to oral drug delivery.
  • Review of companies and technologies developing oral formulations of peptides and small proteins, highlighting stage of development, indications and competitive nature of the area.
  • Providing an understanding of the specific problems involved in transitioning intravenous peptides to oral delivery and the mechanisms of crossing the GI mucosa, together with a review of approaches utilized.
  • Analysis of sales data, growth rates, market share, generic entrants, new products for therapeutic areas in which the new products using the new technologies will compete.
  • Assessment of market potential of the new osdds products in relation to the current market and competitors.
Scope of this report
  • Get a comprehensive understanding of the range of new innovative osdds technologies and how they can overcome problems with the original active ingredient.
  • Identify potential novel technologies which might allow you to overcome a problem with your own drug portfolio or which would allow you to extend your products’ franchise in the market place.
  • Allow you to identify potential licensing opportunities or collaborations with innovative technology companies and assess the potential with respect to recent products commercialized.
  • Allows you to identify which companies and which therapeutic areas are successful in gaining backing for their technologies and those that are not.
  • Identify the time scales, hurdles and progress in developing new innovative technologies such as nanotechnologies/nanomedicines, oral peptides and proteins, new prodrugs and assess market factors affecting the developments and their success/failure.
Key Market Issues
  • Asthe population ages and those elderly people live longer there is a greater need for better drugs which treat chronic conditions associated with aging such as Alzheimer’s disease, Parkinson’s disease, osteoporosis, rheumatoid arthritis, osteoarthritis, type 2 diabetes and obesity,cancer, hypertension and heart disease.
  • The specific challenges in providing for mentally ill patients in which compliance is a problem is driving the demand for formulations which get over problems with swallowing difficulties, frequent dosing, variability in oral absorption or bioavailability,unacceptable side effect potential .
  • The low numbers of new chemical entities approved annually (around 30 compared to 40-50 three decades ago), the record number of blockbuster drugs becoming generic up to 2012 and the first-generation delayed-release products losing patent protection is depressing the sales value in certain billion dollar therapy markets.
Key findings from this report
  • The development of oral peptide hormones is a highly competitive area with many companies developing oral versions of the same peptide and these products will have to compete with new developments in inhaled peptides and very long-duration transdermal or sc depot products which are several years ahead of oral formulations.
  • The failure of Exubera (inhaled insulin) has had a knock on effect on the development of new oral insulins with investors seeing oral insulins as being more risk prone and in addition the issues encountered with some oral insulins has meant that some companies are no longer considering this area a key focus.
  • Many dds companies have switched their development focus to new oral GLP-1 analogs for the treatment of type 2 diabetes and obesity in the light of Byetta’s success but these oral products are several years behind the development of new long-acting transdermal, injectable and inhaled GLP-1 analogs .
  • Generic nasal calcitonin products have depressed the value of second-generation nasal preparations which are still patent protected thus this does not bode well for prices achievable for oral salcatonin products which are nearing the market as they have to offer better therapeutic outcomes in order to achieve higher prices and ultimately market share.
Key questions answered
  • What oral peptide products have the greatest growth potential and how far along the development path have they reached?
  • What are the strategies employed by brand leaders to protect their franchise in the $10 billion US antiepileptic market in the face of recent generic competition?
  • How has the failure of Exubera (inhaled insulin) affected the oral insulin developments and oral peptides in general?
  • What are the main diseases and how advanced are the oral peptide and protein formulations?
  • How successful is prodrug technology in terms of drug development and what are the latest developments?
  • What innovative companies and platform technologies are attracting investment and collaboration agreements?
About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , , |

ReportsandReports - Innovations in Combating Infectious Diseases: Opportunities in therapeutics and diagnostics through application of proteomics, genomics, nanotechnology, and novel sources of lead generation



Infectious disease is not merely a problem of the past; despite significant breakthroughs achieved during the last century in the development of antibiotic, antiviral, and antiparasitic drugs and vaccines, the eradication or even control of many infectious diseases has not been accomplished. Of particular current concern are the problems of rapidly developing drug resistance, emerging disease, re-emerging disease, the threat of bioterrorism, and the speed of reaction to the appearance of virulent strains posing pandemic threats. Furthermore, the effective treatment of infectious diseases is dependent on accurate and rapid diagnosis, and this in itself can present significant challenges, especially in cases where the disease progression is poorly understood or has long asymptomatic latency (such as prion diseases).

Successful drugs and vaccines against infectious agents that put millions of people at risk have potentially lucrative markets. The key to developing those drugs is to understand the pathogenic process and gain insight into where and how it can best be interrupted. This report makes a detailed and comprehensive analysis of the cutting edge of research aiming to reveal how bacteria, viruses, fungi, and prions infect and affect their hosts. It also assesses the new technologies and techniques that are being used to design and develop the anti-infective drugs and diagnostic methods of the 21st century.

Key features of this report

This report presents a snapshot of how new technologies and approaches are being applied to the discovery of new drug targets, vaccine candidates, lead compounds, and novel delivery systems that will enhance diagnostics and therapeutics across the whole range of infectious diseases:
  • How proteomics is being used to identify biomarkers for new diagnostics in infectious diseases
  • How proteomics is being used to identify novel targets for drug discovery and vaccine development in infectious diseases
  • The impact of genomics on the search for novel targets for infectious disease drug discovery
  • Novel natural sources for lead generation in infectious diseases
  • Lead optimization techniques relevant to infectious diseases
  • How the application of nanobiotechnology is impacting on drug discovery and drug delivery in infectious diseases
Scope of this report
  • Gain awareness of the most significant areas of unmet need for anti-infective drug development.
  • Build knowledge of the most promising diagnostics research – ripe for commercialization – for MRSA and community-acquired infections, bacterial meningitis, periodontal disease, and innovative ways for predicting outcome in hepatitis infections.
  • Discover how proteomics and genomics are making an increasing impact on drug development programs, and how important infectious agents can be tackled by drug and vaccine approaches.
  • Identify the new opportunities for small and large biotechnology based companies to undertake vaccine development based on proteomic and genomic studies
Key Market Issues
  • More accurate and rapid diagnostics will remain a pressing need combating prion diseases, sexually transmitted diseases, HIV, hospital-acquired infections and bioterrorism threats.
  • Diagnostics is a big area that is ripe for more commercial development, particularly for diagnostic kits that are fast and simple to operates by unskilled personnel, making them amenable to the point-of-care use.
  • Personalized medicine will remain a priority; drug treatments need to be more tailored and efficient with fewer side effects, less frequent dosing, and faster action..
  • Using genomics to monitor and carry out surveillance of infectious disease will become more important and more necessary, so that new outbreaks, spread of disease, and danger of pandemics can be better monitored and predicted by global warning systems.
  • The need to identify, monitor, and respond to bioterrorism will continue to drive research into lethal viral infections such as small pox and ebola, and bacterial diseases such as anthrax and plague.
Key findings from this report
  • Drug development, vaccine development, and novel approaches to therapeutics are needed urgently for bacterial, viral, fungal, and prion diseases, which cause high morbidity and mortality in both the developing and the developed world.
  • To date, there has been an intensive research effort to use proteomics to detect, identify, characterize, and validate biomarkers and protein signatures in diagnostics for many different infectious diseases but validation and commercialization has so far proved relatively elusive.
  • Drug resistance, emerging infections and the threat of bioterrorism make the understanding of virulence factors and disease pathogenesis essential to form a springboard from which to launch drug discovery programs.
  • Genomics is being applied to drug discovery across the spectrum of infectious diseases, whether they are caused by bacteria, viruses, fungi, parasites, or prions. Genomic data can be used in public health surveillance and monitoring of infectious diseases, particularly when there is a threat of a pandemic or bioterrorist attack.
  • Novel sources of lead compounds to screen against newly discovered targets are much needed; natural sources have already provided the starting point for several successful anti-infectives, and many sources remain to be explored.
Key questions answered
  • Which areas of drug development in infectious disease could have the greatest impact?
  • How can the relatively new technology of proteomics be used to develop leads for drug development?
  • How are proteomic techniques being used in the design and production of modern diagnostic tools for infectious diseases?
  • How are genomic technologies changing the way lead compounds are generated and providing ideas for innovative targeted drugs?
  • In which bacteria, viral, fungal and prion diseases are fundamental research efforts showing the most potential for identifying compounds suitable for drug development?
About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , , , , , |